Gilteritinib and CAR T-cell therapy in high-risk pediatric leukemias
3 Views
administrator
07/14/23
Sarah Tasian, MD, Children's Hospital of Philadelphia, Philadelphia, PA, discusses strategies to treat pediatric FLT3-mutant acute myeloid leukemia (AML) and KMT2A-rearranged acute lymphoblastic leukemia (ALL). Pre-clinical studies investigating gilteritinib, a FLT3 inhibitor, have demonstrated that combining gilteritinib and chimeric antigen receptor (CAR) T-cell therapy was effective in the aforementioned patients. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
Show more
Facebook Comments
No comments found